Benzinga | Aug 18, 2020 08:01AM EDT

Biocept Awarded US Patent For proprietary Primer-Switch Mutation Detection And Amplification Improvement Platform Used To Detect Rare Cell Mutations, Including Cancer Biomarkers

SAN DIEGO, Aug. 18, 2020 /PRNewswire/ --Biocept, Inc. (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that it has been granted US Patent number: 10,745,749, entitled METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS. The patent provides intellectual property protection for Primer-Switch technology, which is useful for the detection of rare cell mutations using circulating tumor DNA (ctDNA) analysis through real-time PCR and associated analysis methods, including next-generation sequencing (NGS).